Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H15NO2S |
Molecular Weight | 273.35 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)C[S@+]([O-])C(C1=CC=CC=C1)C2=CC=CC=C2
InChI
InChIKey=YFGHCGITMMYXAQ-IBGZPJMESA-N
InChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/t19-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15467232Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22537794
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15467232
Curator's Comment: Description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22537794
(+)-modafinil is an enantiomer of modafinil, a wake-promoting agent, that primarily affects areas of the brain involved in controlling wakefulness. (+)-enantiomer of modafinil was clarified to be S-configuration. The optical enantiomers of modafinil have similar pharmacological actions. Both modafinil enantiomers bind in vitro to the dopamine transporter and inhibit dopamine reuptake with the R- slightly more potent than the S-enantiomer. As a component of racemic mixture (+)-modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26338061 |
48.62 µM [IC50] | ||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22537794 |
8.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PROVIGIL Approved UsePROVIGIL (1:1 racemic mixture of S- and R-modafinil enantiomers) is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. Launch Date1998 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID70457709
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY | |||
|
11173366
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY | |||
|
1445415
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY | |||
|
77591
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY | |||
|
112111-47-4
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY | |||
|
152JRG3T0U
Created by
admin on Sat Dec 16 10:49:55 GMT 2023 , Edited by admin on Sat Dec 16 10:49:55 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD